Evolutionary Oncology: A New Research Validates This Approach in Preclinical Models

/in , /by

Researchers at Trinity College Dublin and Moffitt Cancer Center have uncovered a promising prostate cancer breakthrough: radiation-resistant tumor cells become unexpectedly vulnerable to attack by natural killer (NK) immune cells, presenting a strategic “evolutionary double-bind” that could transform treatment approaches. This discovery challenges traditional views of therapy resistance, showing that when prostate cancer cells adapt […]

Read more

Ultrasound Nanobubbles Crack Prostate Cancer’s Collagen Fortress Improving Immunotherapy Penetration

/in , , /by

Researchers at Case Western Reserve University used tiny ultrasound-activated nanobubbles to dismantle the tough collagen walls that shield solid tumors from treatments. These “fortresses” made of stiff, crosslinked collagen block immune cells and drugs from reaching cancer cells deep inside, a major hurdle in fighting aggressive tumors like prostate cancer. The nanobubbles, filled with inert […]

Read more

KLS-3021 An Oncolytic Viral Therapy For Prostate Cancer Could Soon Reach Clinical Trial Stage

/in , /by

KLS-3021 represents a promising advancement in oncolytic virus therapy, particularly for prostate cancer, where it has shown potential to address unmet needs in early and locally advanced disease. This recombinant vaccinia virus is engineered to selectively infect and lyse tumor cells while delivering a triple payload of therapeutic genes: PH-20 hyaluronidase to degrade the tumor’s […]

Read more

Dual-Action Nanomaterial Eradicates Cancer Cells And Spares Healthy Tissue

/in /by

Scientists at Oregon State University have pioneered a groundbreaking nanomaterial that selectively annihilates cancer cells by harnessing the tumors’ own hostile chemical environment, while leaving healthy tissues completely unscathed. This innovative approach, detailed in a recent study published in Advanced Functional Materials, represents a major leap in chemodynamic therapy (CDT), an emerging treatment strategy that […]

Read more

Nanotech Advancement: Relief from Prostate Cancer Bone Pain on the Horizon

/in , /by

A promising study published this month in Science Advances introduces a promising “neuroimmunotherapy” nanocarrier called LipoNCs@pGSDMB, designed precisely for bone metastases like those in prostate cancer. This tiny, smart drug delivery system activates only in the high-oxidative-stress environment of bone tumors, fusing directly with cancer cell membranes to release its payload straight into the cell’s […]

Read more

SHR-A1921: A Next-Generation TROP2-Targeted Antibody-Drug Conjugate Shows Promise in Prostate Cancer

/in , /by

SHR-A1921, also known as tizetatug rezetecan, represents a significant advancement in targeted cancer therapeutics, specifically designed to exploit TROP2 overexpression in aggressive malignancies including prostate cancer. This novel antibody-drug conjugate (ADC) has demonstrated compelling preclinical activity in prostate cancer models and encouraging early clinical results across multiple solid tumors, positioning it as a potential therapeutic […]

Read more

Recent Discovery on tRNA Halves in Prostate Cancer

/in /by

Tiny pieces of genetic material called tRNA halves play a surprising role in fueling prostate cancer growth, according to new research published in PLOS Biology. These molecules form when normal tRNA, short strands of RNA that help build proteins, get split in half inside cells, especially those driven by male hormones like in prostate cancer. […]

Read more

Smart Antibody Medicines: How the ALCO5 Platform Could Upgrade Targeted Cancer Therapy

/in , , /by

ALCO5 is a new way of building “smart” cancer drugs that combine an antibody with a powerful medicine in a single, targeted package. The aim is to hit cancer cells much harder while sparing as much healthy tissue as possible, and to do this with drug types that previously could not be used in these […]

Read more

Stem Cell Breakthrough Enables Scalable Helper T Cell Therapies

/in , /by

Researchers at the University of British Columbia have achieved a major advance in stem cell engineering by developing a reliable method to produce helper T cells from stem cells in a controlled lab environment. This breakthrough, detailed in the journal Cell Stem Cell, tackles a persistent obstacle in cell therapy production, making treatments more affordable […]

Read more

Deciparticle Everolimus: Reviving mTOR Inhibition for Neuroendocrine Prostate Cancer?

/in , /by

Sapu-003, a nanoparticle-formulated version of everolimus delivered via a new platform (Deciparticle) has received approval for first-in-human Phase 1 testing in breast cancer patients, representing a major advance in intravenous oncology drug delivery. Unlike the standard oral everolimus tablet, which achieves only 10-20% bioavailability due to extensive first-pass metabolism and gastrointestinal degradation, the Deciparticle platform […]

Read more